Leukemia News

CHICAGO — Interim results from a phase 2 study showed positive survival outcomes for individuals who underwent peripheral blood stem cell transplantation for hematologic malignancies.

CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO Annual Meeting.

Participation in cancer-related clinical trials could increase dramatically if researchers screened and recruited individuals using routine care patient-reported outcomes, according to results published in JAMA Oncology.

Active cancer treatment is associated with increased risk for sudden cardiac death, especially among patients younger than 74 years old and those with a history of heart failure, results from a retrospective study showed.

The amount of autologous and allogeneic hematopoietic stem cell transplants for hematologic disorders has increased over time in tandem with longer survival, according to results of an observational study.

The next evolution of gene therapies may involve pitting T cells with different modifications against one another in a “race” inside a human to determine which edits produce the best results against a tumor, an expert panel predicted.

Patients participating in clinical trials for anticancer drugs do not gain a survival benefit compared with individuals who received routine care, according to study results published in JAMA.

AI could have the ability to answer some patient questions on cancer instead of clinicians, reducing clinician burdens and improving access to care, according to study results published in JAMA Oncology.

The gap in cancer mortality between Black and white individuals shrunk dramatically during the past 3 decades, according to a new report.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses how advances in the understanding of prognostic biomarkers may help guide the treatment of AML.